
|Videos|September 10, 2019
The Future of Personalized Therapy in Advanced HCC
Advertisement
Key Takeaways:
Novel approaches in the treatment of advanced hepatocellular carcinoma, such as using modified T-cell receptors to attack liver tumors with alpha fetoprotein expression.
Biomarker-based approaches to target the FGF19—FGFR4 signaling pathway, with a new generation of molecules in patients with hepatocellular carcinoma and high-FGF19 amplification or expression.
Moving toward a more personalized approach in the treatment of hepatocellular carcinoma.
Ensuring patients with hepatocellular carcinoma are not decompensated during initial locoregional therapy, so they may benefit from the sequencing of current and future therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5




































